Acorda Therapeutics’ (ACOR) “Hold” Rating Reiterated at JPMorgan Chase & Co.

Acorda Therapeutics (NASDAQ:ACOR)‘s stock had its “hold” rating reaffirmed by equities researchers at JPMorgan Chase & Co. in a research report issued on Tuesday, May 7th, Stock Target Advisor reports. They currently have a $18.00 target price on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 93.76% from the company’s current price.

Several other analysts also recently commented on ACOR. Zacks Investment Research downgraded shares of Acorda Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 28th. BidaskClub downgraded shares of Acorda Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, March 22nd. Oppenheimer reaffirmed a “hold” rating on shares of Acorda Therapeutics in a report on Tuesday, March 19th. Cowen reissued a “buy” rating and issued a $30.00 price objective on shares of Acorda Therapeutics in a report on Monday, January 7th. Finally, ValuEngine downgraded shares of Acorda Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, January 24th. Four equities research analysts have rated the stock with a sell rating, six have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Acorda Therapeutics has a consensus rating of “Hold” and an average target price of $19.30.

ACOR stock traded down $0.09 during midday trading on Tuesday, hitting $9.29. The company’s stock had a trading volume of 873,944 shares, compared to its average volume of 872,602. The firm has a market capitalization of $462.53 million, a P/E ratio of 5.10 and a beta of 1.34. Acorda Therapeutics has a twelve month low of $9.10 and a twelve month high of $36.35. The company has a current ratio of 4.30, a quick ratio of 3.97 and a debt-to-equity ratio of 0.66.

Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.51. The company had revenue of $44.14 million for the quarter, compared to analyst estimates of $35.14 million. Acorda Therapeutics had a negative net margin of 1.40% and a positive return on equity of 9.34%. Acorda Therapeutics’s revenue for the quarter was down 58.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.14 EPS. As a group, equities research analysts forecast that Acorda Therapeutics will post -4.11 EPS for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in the stock. Man Group plc raised its position in Acorda Therapeutics by 1,549.6% in the third quarter. Man Group plc now owns 88,929 shares of the biopharmaceutical company’s stock worth $1,747,000 after purchasing an additional 83,538 shares in the last quarter. MetLife Investment Advisors LLC increased its holdings in shares of Acorda Therapeutics by 55.9% during the third quarter. MetLife Investment Advisors LLC now owns 31,894 shares of the biopharmaceutical company’s stock worth $627,000 after buying an additional 11,439 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Acorda Therapeutics by 436.3% during the third quarter. AQR Capital Management LLC now owns 121,471 shares of the biopharmaceutical company’s stock worth $2,386,000 after buying an additional 98,822 shares in the last quarter. Teachers Advisors LLC increased its holdings in shares of Acorda Therapeutics by 71.7% during the third quarter. Teachers Advisors LLC now owns 157,178 shares of the biopharmaceutical company’s stock worth $3,089,000 after buying an additional 65,634 shares in the last quarter. Finally, TIAA CREF Investment Management LLC increased its holdings in shares of Acorda Therapeutics by 29.1% during the third quarter. TIAA CREF Investment Management LLC now owns 222,067 shares of the biopharmaceutical company’s stock worth $4,364,000 after buying an additional 50,083 shares in the last quarter.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.

Featured Story: Options Trading

Analyst Recommendations for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.